Valiant Laboratories Limited (NSE:VALIANTLAB)
India
· Delayed Price · Currency is INR 55.72
-0.05 (-0.09%)
Mar 10, 2026, 9:15 AM IST
Valiant Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| Revenue | 2,033 | 1,334 | 1,821 | 3,339 | 3,124 |
| Revenue Growth (YoY) | 91.43% | -26.74% | -45.48% | 6.90% | - |
| Cost of Revenue | 1,737 | 1,170 | 1,705 | 2,789 | 2,530 |
| Gross Profit | 295.74 | 163.9 | 115.76 | 549.82 | 594.07 |
| Selling, General & Admin | 55.62 | 43.88 | 43.13 | 46.13 | 33.44 |
| Other Operating Expenses | 185.95 | 166.81 | 156.71 | 152.79 | 101.43 |
| Operating Expenses | 277.88 | 231.62 | 219.49 | 214.55 | 159.13 |
| Operating Income | 17.86 | -67.72 | -103.73 | 335.28 | 434.94 |
| Interest Expense | -9.44 | -1.74 | -0.78 | -2.54 | -0.36 |
| Interest & Investment Income | 30.27 | 30.27 | 26.77 | 0.97 | 8.31 |
| Currency Exchange Gain (Loss) | -0.15 | -0.15 | 2.89 | 5.83 | 8.72 |
| Other Non Operating Income (Expenses) | -36.53 | 19.48 | 58.74 | 3.45 | 1.05 |
| EBT Excluding Unusual Items | 2.01 | -19.86 | -16.11 | 342.99 | 452.66 |
| Gain (Loss) on Sale of Investments | 4.73 | 4.73 | 8.42 | 38.37 | - |
| Pretax Income | 6.75 | -15.13 | -7.7 | 381.36 | 452.66 |
| Income Tax Expense | 50.06 | 6.89 | -10.89 | 91.38 | 111.93 |
| Net Income | -43.31 | -22.01 | 3.2 | 289.98 | 340.74 |
| Net Income to Common | -43.31 | -22.01 | 3.2 | 289.98 | 340.74 |
| Net Income Growth | - | - | -98.90% | -14.89% | - |
| Shares Outstanding (Basic) | 52 | 43 | 38 | 33 | 33 |
| Shares Outstanding (Diluted) | 52 | 43 | 38 | 33 | 33 |
| Shares Change (YoY) | 24.80% | 14.33% | 16.72% | - | - |
| EPS (Basic) | -0.84 | -0.51 | 0.08 | 8.91 | 10.46 |
| EPS (Diluted) | -0.84 | -0.51 | 0.08 | 8.91 | 10.46 |
| EPS Growth | - | - | -99.06% | -14.88% | - |
| Free Cash Flow | - | -1,125 | -439.85 | 183.7 | 49.48 |
| Free Cash Flow Per Share | - | -25.90 | -11.57 | 5.64 | 1.52 |
| Gross Margin | 14.55% | 12.29% | 6.36% | 16.47% | 19.02% |
| Operating Margin | 0.88% | -5.08% | -5.70% | 10.04% | 13.92% |
| Profit Margin | -2.13% | -1.65% | 0.18% | 8.68% | 10.91% |
| Free Cash Flow Margin | - | -84.37% | -24.16% | 5.50% | 1.58% |
| EBITDA | 37.83 | -48.7 | -85.98 | 349.23 | 456.55 |
| EBITDA Margin | 1.86% | -3.65% | -4.72% | 10.46% | 14.62% |
| D&A For EBITDA | 19.97 | 19.02 | 17.75 | 13.95 | 21.61 |
| EBIT | 17.86 | -67.72 | -103.73 | 335.28 | 434.94 |
| EBIT Margin | 0.88% | -5.08% | -5.70% | 10.04% | 13.92% |
| Effective Tax Rate | 742.15% | - | - | 23.96% | 24.73% |
| Revenue as Reported | 2,031 | 1,388 | 1,917 | 3,388 | 3,149 |
Source: S&P Capital IQ. Standard template. Financial Sources.